Non-therapeutic use of at least one crystalline form of copper salicylate, with a molar ratio between copper and salicylic acid of (1: 1), selected from crystalline form I, crystalline form II or crystalline form III and / or mixtures thereof ； wherein crystalline form I is characterized by an orthorhombic crystal structure, a unit crystalline cell indicated later in Table 1, an FTIR spectrum having at least the absorption bands indicated later in Table 2, an XRD spectrum that it has at least the characteristic peaks indicated below in Table 3 and, preferably, a particle size distribution ranging from 1.95 µm to 19.40 µm, preferably equal to about 6.17 µm； wherein the crystalline form II is characterized by a triclinic crystal structure, a unit crystalline cell indicated below in Table 1, an FTIR spectrum having at least the absorption bands indicated below in Table 2, an XRD spectrum that it has at least the characteristic peaks indicated below in Table 3 and, preferably, a particle size distribution ranging from 15.37 µm to 100.30 µm, preferably equal to about 49.45 µm； wherein crystalline form III is characterized by a two-dimensional crystal structure, a unit crystalline cell indicated later in Table 1, an FTIR spectrum having at least the absorption bands indicated later in Table 2, an XRD spectrum that it has at least the characteristic peaks indicated later in Table 3 ** (See table) ** for the control of phytopathogenic bacteria.Uso no terapéutico de al menos una forma cristalina de salicilato de cobre, con una relación molar entre cobre y ácido salicílico de (1:1), seleccionada de forma cristalina I, forma cristalina II o forma cristalina III y/o mezclas de las mismas； en el que la forma cristalina I se caracteriza por una estructura cristalina ortorrómbica, una celda cristalina unitaria indicada posteriormente en la Tabla 1, un espectro de FTIR que tiene al menos las bandas de absorción indicadas posteriormente en la Tabla 2, un espectro de XRD que tiene al
